rights issue, page-6

I'm not a big fan of the rights issue. However, for what it's worth, my understanding is that the company hoped it would relieve the perception that AVX would run out of cash, provide leverage in the licensing discussions and reward existing shareholders with an offer of shares at $0.07. That's a pretty optimistic view, however everything I've read and heard strongly suggests their discussions re partnering are active and with more than one company. Some want to see the 16 week result to sort out the dosing issue, some mulling over the recent phase 2 96 week data. They've got a difficult task in this environment, but I'm not too sure about whether this rights issue helps much. Time will tell I guess. Good luck to holders. Sorry to see you go jdg - hope you've left too early though. I'm staying in.